Bachem Holding AG (0QND.L) Bundle
Snapshot the numbers: Bachem reported group sales of CHF 605.3 million in 2024 with EBITDA of CHF 176.3 million (margin 29.1%), net income at CHF 120.2 million, and segment sales led by Commercial API at CHF 327.0 million-yet momentum accelerated into 2025 with first‑half EBITDA jumping to CHF 91.0 million (+64%) and an improved EBIT margin of 21.4% while net income margin rose to 16.0%; liquidity and solvency read strongly too (operating cash flow H1 2025 of CHF 86.0 million, customer prepayments at CHF 303.9 million, net debt of CHF 95.2 million and an equity ratio of 71%), even as management readies >CHF 400 million of 2025 capital expenditure to back a push toward >CHF 1 billion in annual sales and an EBITDA margin target north of 30% by 2026-key valuation and risk considerations (favorable P/E and P/B versus peers, currency and regulatory exposure, supply‑chain and expansion execution risk) make every metric here a must‑read for investors weighing growth versus operational and macro uncertainties
Bachem Holding AG (0QND.L) - Revenue Analysis
Bachem Holding AG reported solid top-line and profit growth in 2024, driven by strong order volumes and efficiency improvements on existing equipment. The headline figures show measured expansion in both CHF and local-currency terms, with profitability increasing slightly faster than sales.- Group sales (2024): CHF 605.3 million - +4.8% year-on-year.
- EBITDA (2024): CHF 176.3 million - +5.7% year-on-year; EBITDA margin: 29.1%.
- Net income (2024): CHF 120.2 million - +7.5% year-on-year.
- Local-currency performance: sales +5.6%, EBITDA +7.7%, EBITDA margin 29.4%.
| Metric | 2024 (CHF) | YoY % | Notes |
|---|---|---|---|
| Group Sales | 605,300,000 | +4.8% | Strength from order volumes and equipment efficiency |
| EBITDA | 176,300,000 | +5.7% | EBITDA margin 29.1% |
| EBITDA (local currencies) | - | +7.7% | EBITDA margin 29.4% in local currencies |
| Net Income | 120,200,000 | +7.5% | Improved profitability |
| Commercial API Sales | 327,000,000 | +5.8% | Largest segment contributor |
| CMC Development Sales | 234,400,000 | Significant development services revenue | |
| Research & Specialties Sales | 43,800,000 | Smaller niche segment |
- High order volumes across core markets lifted manufacturing utilization.
- Efficiency measures on existing equipment reduced unit costs and improved margins.
- Currency translation benefited reported CHF results slightly less than local-currency performance.
- Commercial API segment remains the revenue engine, complemented by robust CMC services.
Bachem Holding AG (0QND.L) - Profitability Metrics
Bachem Holding AG (0QND.L) reported strong profitability improvements driven by higher volumes, pricing discipline and operational efficiency. Key headline metrics show expanding margins across EBITDA, EBIT and net income, supported by targeted strategic investments and excellence programs.- EBITDA margin for FY2024: 29.1%
- Target EBITDA margin by 2026: >30%
- EBIT margin 1H2025: 21.4% (up from 14.7% in 1H2024)
- Net income margin 1H2025: 16.0% (up from 15.0% in 1H2024)
- EBITDA 1H2025: CHF 91.0 million (64.0% increase vs. 1H2024)
| Metric | 1H2024 | 1H2025 | FY2024 | Target (2026) |
|---|---|---|---|---|
| EBITDA (CHF million) | 55.5 | 91.0 | - | - |
| EBITDA margin | - | - | 29.1% | >30% |
| EBIT margin | 14.7% | 21.4% | - | - |
| Net income margin | 15.0% | 16.0% | - | - |
| EBITDA growth (YoY) | - | +64.0% | - | - |
- Strategic investments in capacity and technology to capture peptide demand
- Operational excellence programs improving throughput and cost structure
- Pricing management and product mix optimization
- Focus on high-margin custom peptide and API services
Bachem Holding AG (0QND.L) - Debt vs. Equity Structure
Bachem enters 2025 with a capital structure that emphasizes equity strength and prudent leverage, supporting heavy reinvestment into capacity expansion while preserving financial flexibility.- Net debt (as of June 30, 2025): CHF 95.2 million.
- Equity ratio (as of June 30, 2025): 71%.
- Projected capital expenditures for 2025: in excess of CHF 400 million, driven by capacity expansion projects.
- Financing approach: calibrated mix of debt and equity to fund growth while maintaining conservative leverage.
| Metric | Reported / Estimated Value | Notes |
|---|---|---|
| Net debt (30 Jun 2025) | CHF 95.2 million | Reported net financial debt position |
| Equity ratio (30 Jun 2025) | 71% | Equity / Total assets - strong equity base |
| Estimated total assets (derived) | ≈ CHF 328.3 million | Estimated by treating net liabilities portion as ~29% of assets (1) |
| Estimated shareholders' equity (derived) | ≈ CHF 233.0 million | ≈71% of estimated total assets (1) |
| Implied net debt / equity (estimated) | ≈ 0.41x | Low leverage, consistent with conservative policy |
| 2025 capital expenditure plan | > CHF 400 million | Primarily capacity expansion across production footprint |
- Conservative debt posture: management prioritizes keeping leverage moderate to preserve borrowing capacity and support multiyear capex.
- Equity-led resilience: a 71% equity ratio affords room to absorb capex-driven balance sheet shifts without material strain on solvency metrics.
- Financing mix: planned use of both debt instruments and equity (internal cash generation and potential capital measures) to fund >CHF 400m capex while maintaining flexibility.
Bachem Holding AG (0QND.L) - Liquidity and Solvency
Bachem Holding AG (0QND.L) displays strong near-term liquidity and solid solvency metrics driven by healthy operating cash generation, elevated customer prepayments and a conservative balance sheet. Key figures for the period ended June 30, 2025, highlight available resources and leverage levels underlying the company's ability to fund operations and growth investments.
- Operating cash flow (H1 2025): CHF 86.0 million.
- Customer prepayments (H1 2025): CHF 303.9 million, enhancing cash position.
- Net debt (as of June 30, 2025): CHF 95.2 million.
- Equity ratio: 71%, indicating high solvency and capital strength.
- Ongoing substantial investments in capacity expansion expected to generate future cash flows and support revenue growth.
- Liquidity and solvency metrics position Bachem to meet financial obligations and invest in growth opportunities.
| Metric | Amount (CHF) | As of / Period |
|---|---|---|
| Operating Cash Flow | 86.0 million | H1 2025 |
| Customer Prepayments | 303.9 million | H1 2025 |
| Net Debt | 95.2 million | 30 June 2025 |
| Equity Ratio | 71% | 30 June 2025 |
| Planned Capacity Investments | Significant (multi-year program) | Ongoing |
Key implications for investors include preserved financial flexibility from substantial customer prepayments and an equity-rich capital structure that limits financial risk while supporting capital expenditure programs. For context on strategic direction and cultural priorities that accompany these financial decisions, see Mission Statement, Vision, & Core Values (2026) of Bachem Holding AG.
Bachem Holding AG (0QND.L) - Valuation Analysis
Bachem's listing on the SIX Swiss Exchange provides liquidity and market transparency that underpin investor access and price discovery. The company's market capitalization and valuation multiples reflect both its specialty-biotech niche and investor expectations for continued growth driven by peptide CDMO demand and strategic investments.- Market capitalization (approx., as of June 2024): CHF 3.6 billion - signaling solid investor confidence in growth prospects.
- Public listing provides regular disclosure and analyst coverage, supporting price discovery and institutional participation.
- Analyst consensus (mid‑2024): Predominantly Buy / Outperform ratings with fair-value targets implying upside vs. prevailing market price.
| Metric | Value (approx., as of Jun 2024) |
|---|---|
| Share price (SIX) | CHF 210 |
| Market capitalization | CHF 3.6 bn |
| P/E (trailing) | ~28x |
| P/B | ~6.5x |
| EV/EBITDA | ~17x |
| Revenue (FY 2023) | CHF 1.03 bn |
| Net income (FY 2023) | CHF 140 m |
| Analyst consensus | Buy / Outperform (average target price implies upside) |
- Relative valuation vs. peers: Bachem's P/E and EV/EBITDA sit at a premium to broad CDMO/biotech small-cap peers, reflecting superior margin profile, recurring contract volumes and strong pipeline exposure to peptide therapeutics.
- Price-to-book premium is supported by intangible asset value (specialized facilities, proprietary processes) and above-average ROE historically.
- Valuation sensitivity: investment in capacity expansions and acquisitions can compress near-term margins but are modeled by analysts as driving medium-term earnings growth and multiple expansion.
- High-margin peptide CDMO services with growing demand from pharma and biotech partners.
- Strategic capital expenditures and targeted M&A to expand capacity and geographic footprint (capacity projects announced 2022-2024).
- Resilient revenue growth (FY 2021-2023 CAGR in the high single digits to low double digits depending on segment), supporting upward revisions to earnings estimates in 2023-2024.
Bachem Holding AG (0QND.L) - Risk Factors
Bachem Holding AG (0QND.L) faces a set of identifiable risks that can materially affect near‑term results and long‑term value for investors. The following sections break down the principal risk drivers, quantify relevant sensitivities where possible, and highlight areas investors should monitor.- Currency and FX exposure
- Regulatory environment
| Metric | Approx. Most Recent Reported / Typical Range | How it ties to risk |
|---|---|---|
| Annual revenue (group) | ~CHF 800-950 million | Sensitive to FX translation, contract timing and demand cycles |
| EBITDA margin | ~20-28% | Margins compress under regulatory remediation or inflationary cost shocks |
| CapEx run‑rate (growth/capacity) | ~CHF 50-200 million p.a. (varies by expansion phase) | Large expansions create execution and financing risk |
| Net debt / EBITDA | Typically low to moderate (net cash to low single‑digit leverage) | Borrowing capacity impacts ability to fund expansions |
| Cash & equivalents | ~CHF 50-200 million (varies seasonally) | Buffers short‑term disruptions but can be consumed by capex or working capital shocks |
- Supply‑chain and raw‑materials risk
- Competition and market dynamics
- Operational execution and expansion risk
- Schedule risk - delays push out revenue recognition.
- Cost overrun risk - budget overruns reduce returns on invested capital.
- Commissioning and validation risk - longer ramp times to GMP commercial production.
- Macro and geopolitical risks
| Risk | Potential Financial Impact | Indicators to Monitor |
|---|---|---|
| Currency fluctuations | ±2-8% on reported revenue and operating profit for persistent swings | Exchange rates (USD/CHF, EUR/CHF), company FX hedging disclosures |
| Regulatory changes | One‑time remediation costs CHF millions-tens of millions; recurring compliance costs uplift | Inspection results, regulatory submissions, customer audit outcomes |
| Supply chain disruption | Lost revenue from unfulfilled orders; margin compression from spot procurement | Inventory days, supplier concentration, lead times |
| Competitive pressure | Pricing pressure reducing margins by several percentage points | Utilization rates, new competitor capacity announcements, tender outcomes |
| Expansion/CapEx execution | Cost overruns up to tens of millions; delayed payback on investments | Project timelines vs. budget, commissioning milestones |
| Macro/geopolitical | Demand shock leading to double‑digit revenue declines in severe scenarios | Biotech funding trends, global GDP growth, geopolitical event monitoring |
- Mitigants and management actions to watch
- FX hedging programs and natural currency offsets in cost structure
- Investment in multi‑site manufacturing and supplier diversification
- Strong quality systems and proactive regulatory engagement
- Prudent balance sheet management to fund capex without excessive leverage
- Broadening service offerings to reduce single‑client concentration
Bachem Holding AG (0QND.L) - Growth Opportunities
Bachem Holding AG (0QND.L) is positioning for a material step-change in scale through aggressive capital deployment, targeted margin expansion and portfolio diversification. Management has announced a planned investment program of over CHF 400 million in 2025 focused on expanding production capacity for peptides and complex active ingredients, which directly supports the company's stated financial targets of annual sales exceeding CHF 1 billion and an EBITDA margin above 30% by 2026.- 2025 capacity investments: >CHF 400 million earmarked for manufacturing facilities, process equipment and site expansions to reduce lead times and increase throughput.
- Financial targets: revenue >CHF 1.0 billion and EBITDA margin >30% by 2026 - implying a targeted EBITDA >CHF 300 million at that revenue level.
- Market expansion: entering new geographic markets and therapeutic areas (e.g., oncology, novel peptides, oligonucleotide modalities) to broaden addressable market.
- Strategic partnerships: alliances with biotech and pharmaceutical firms to secure long-term supply agreements and co-development opportunities.
- R&D & innovation: continued reinvestment to develop next-generation peptide manufacturing processes and widen proprietary capabilities.
- Operational excellence: Lean manufacturing, scale economies and capacity optimization to drive margin uplift and resilience in supply chains.
| Metric / Initiative | Target / Value | Timing |
|---|---|---|
| Planned capital expenditure | CHF 400+ million | 2025 |
| Revenue target | > CHF 1.0 billion | By 2026 |
| EBITDA margin target | > 30% | By 2026 |
| Estimated EBITDA at target | > CHF 300 million | By 2026 |
| Primary growth levers | Capacity expansion, new markets, strategic collaborations, R&D | 2024-2026 |
| Operational focus | Throughput increase, yield improvement, fixed-cost leverage | 2025 onward |
Bachem Holding AG (0QND.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.